Porcine Brain Neuropeptide Mixture — Neuroprotective Agent
A standardised mixture of neuropeptides and amino acids derived from purified porcine brain protein, with over 50 years of clinical use across Europe and Asia. Cerebrolysin mimics the action of endogenous neurotrophic factors — particularly NGF and BDNF — without crossing the blood-brain barrier intact. One of the most extensively researched neuroprotective compounds available, with clinical trials in Alzheimer's disease, stroke recovery, traumatic brain injury, and vascular dementia.
01 — Research Summary
Cerebrolysin has one of the most substantial clinical evidence bases of any compound in the cognitive peptide space — backed by randomised controlled trials across multiple neurological indications conducted over five decades.
Significant improvement in global clinical outcome and cognitive measures. Meta-analyses of RCTs in Alzheimer's patients show Cerebrolysin produces statistically significant improvements in global clinical outcome scores and cognitive performance — though effect sizes are modest and the field acknowledges methodological heterogeneity across trials.
Improved functional outcomes in acute ischaemic stroke. The CASTA trial — a large multi-centre RCT — demonstrated Cerebrolysin improved functional neurological outcomes at 90 days post-stroke, particularly in patients with moderate to severe deficits. Used as standard care in several Eastern European countries post-stroke.
Slowed cognitive decline and improved daily function. A well-designed RCT in vascular dementia patients showed Cerebrolysin significantly slowed cognitive decline and improved activities of daily living scores over 24 weeks versus placebo — demonstrating efficacy in a distinct dementia subtype from Alzheimer's.
Improved neurological recovery in traumatic brain injury. A pilot RCT in TBI patients showed Cerebrolysin accelerated neurological recovery and improved functional outcomes at 90 days — consistent with its neurotrophic mechanism and generating interest in sports medicine and military medicine contexts.
02 — Mechanism of Action
Cerebrolysin works through mimicking and amplifying endogenous neurotrophic factor activity — the biological signals that maintain neuronal health, promote synaptic plasticity, and support neuronal survival.
Cerebrolysin's active peptide fractions mimic the activity of endogenous neurotrophic factors including NGF (nerve growth factor) and BDNF. The peptides are small enough (<10 kDa) to penetrate the blood-brain barrier while the full proteins cannot.
Cerebrolysin activates intracellular survival signalling pathways (PI3K/Akt, MAPK/ERK) that protect neurons from apoptosis under conditions of ischaemia, oxidative stress, and excitotoxicity — explaining its efficacy in acute injury settings.
By supporting BDNF-like signalling, Cerebrolysin promotes long-term potentiation and synaptic remodelling — the cellular mechanisms of learning and memory consolidation. This is relevant to both acute cognitive enhancement and long-term neuroprotection.
Research documents Cerebrolysin reduces amyloid beta aggregation and inhibits tau hyperphosphorylation in animal models — directly relevant to Alzheimer's pathology and explaining the clinical trial focus on this indication.
Cerebrolysin promotes neurogenesis in the hippocampus — the formation of new neurons — which is impaired in both aging and neurodegenerative disease. This mechanism may underlie long-term functional improvements observed beyond the treatment period.
Cerebrolysin must be administered intravenously or intramuscularly — oral or nasal administration destroys the active peptides. This is the primary practical barrier to its use in community settings and one reason it has not achieved the mainstream community following of nasal peptides like Semax, despite comparable or superior clinical evidence.
03 — Dosing Protocols
Cerebrolysin is typically administered in clinical settings due to the IV/IM route requirement. Community use involves sourcing ampoules and self-administering IM — a more advanced protocol than most peptides.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Cognitive enhancement | 5–10 mL | Daily IM × 10 days | 10-day cycles | Community standard for healthy enhancement. Repeat cycles 2–3x per year. |
| Neuroprotection / longevity | 10 mL | Daily IM × 10–20 days | 2–4x annually | Higher volume and frequency used in longevity-focused protocols. |
| Clinical (stroke / Alzheimer's) | 10–30 mL | Daily IV × 10–21 days | Per clinical protocol | Clinical range from trial data. IV administration in monitored setting. |
| Microdose maintenance | 2–5 mL | 2–3x per week | Ongoing | Lower frequency maintenance between active cycles in some longevity protocols. |
IV administration should only occur under medical supervision. IM self-administration carries infection risk if sterile technique is not rigorously maintained. Rare hypersensitivity reactions have been reported. Cerebrolysin is derived from porcine brain — relevant for certain dietary restrictions. Not approved by the FDA for any indication.
04 — Community Experiences
Cerebrolysin has a smaller but highly dedicated community — primarily experienced biohackers and those with clinical backgrounds willing to manage IV/IM administration. Discussions on r/nootropics and r/Peptides consistently rate it among the most powerful cognitive compounds available, with particular enthusiasm for the acute cognitive clarity reported during 10-day cycles. The IV/IM barrier is frequently cited as the only reason it isn't more widely used.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"Day 3–8 of a 10mL/day IM cycle is genuinely unlike anything else I've tried. Verbal fluency, pattern recognition, processing speed — all elevated simultaneously. The effect fades over 2–3 weeks post-cycle but something structural seems to remain..."
"Semax is the daily driver — reliable, easy to use, good acute effect. Cerebrolysin is the serious intervention — harder to use, more intense effect, better for structural improvement. I use both but they serve different purposes..."
"The IM protocol is less scary than it sounds once you learn proper technique. Use insulin syringes for IM in the thigh, rotate sites, strict sterile technique. The logistics are the only real barrier here — the compound itself is safe and well-studied..."
"Post-concussion syndrome for 18 months. Three 10-day Cerebrolysin cycles over 6 months. The fog progressively lifted in a way that nothing else had achieved. The TBI trial data is consistent with what I experienced..."